Market Cap 68.48M
Revenue (ttm) 0.00
Net Income (ttm) -77.91M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 257,800
Avg Vol 428,260
Day's Range N/A - N/A
Shares Out 42.80M
Stochastic %K 0%
Beta 1.82
Analysts Strong Sell
Price Target $11.50

Company Profile

Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 207 8979
Website: acrivon.com
Address:
480 Arsenal Way, Suite 100, Watertown, United States
Dani_G_German
Dani_G_German Jul. 24 at 2:34 PM
$ACRV back to consolidation unfortunately Hang in there
1 · Reply
nmarrone2207
nmarrone2207 Jul. 23 at 12:18 PM
$ACRV zoom out and can see a LONG tightening consolidation.... if that plays out we are staying in the 1.50-2 range for months.
2 · Reply
Bullbarbise
Bullbarbise Jul. 23 at 12:14 PM
0 · Reply
dgbio
dgbio Jul. 22 at 6:27 PM
$ACRV "ACR-2316 is currently in a Phase 1/2 clinical study advancing toward the dose expansion phase. Initial observations have shown tumor shrinkage, including PRs, and durable clinical benefit in subjects with small cell lung cancer (SCLC), squamous non-small cell lung cancer (sqNSCLC), and adenosarcoma NSCLC (adNSCLC), AP3-predicted tumor types not previously shown to be sensitive to other clinical WEE1 or PKMYT1 inhibitors". https://ir.acrivon.com/news-releases/news-release-details/acrivon-highlight-power-its-ap3-platform-streamlined-pathway
0 · Reply
Dani_G_German
Dani_G_German Jul. 22 at 3:34 PM
$ACRV stick with it
0 · Reply
ajmrtxl
ajmrtxl Jul. 22 at 3:05 PM
$ACRV 's latest squeeze play
0 · Reply
nmarrone2207
nmarrone2207 Jul. 20 at 9:01 PM
$ACRV 4 hour looks ready to turn up....
0 · Reply
open_outcry
open_outcry Jul. 17 at 2:45 PM
$ACRV seems like nearly everyone on this board is trading this stock from a technical standpoint... i'm invested in this one on substance. it's a LOOOONG hold that will be a 10-bagger (or better). seems like the most obvious and lucrative play with this ticker, given it doesn't swing like some other bios ($CCCC)
2 · Reply
elmono
elmono Jul. 16 at 4:50 PM
$ACRV basically a turd 😂😂😂
1 · Reply
Bullbarbise
Bullbarbise Jul. 16 at 2:51 PM
$ACRV weeks to recover a fraction of what lost in the past. And in a single day and after a small recover 2 consecutive vomit days where in few minutes goes to loose all what recoverred. Wasted time, wasted money. Unbeliavable. I'll start to sell my shares and never again. Better spend money in other intelligent ways
1 · Reply
Latest News on ACRV
Acrivon Therapeutics Proxy statement: Proxy filing

May 22, 2026, 8:00 AM EDT - 2 months ago

Acrivon Therapeutics Proxy statement: Proxy filing


Acrivon Therapeutics reports Q1 EPS (49c), consensus (52c)

2026-05-13T21:27:56.000Z - 2 months ago

Acrivon Therapeutics reports Q1 EPS (49c), consensus (52c)


Acrivon Therapeutics Earnings release: Q1 2026

May 13, 2026, 4:00 PM EDT - 2 months ago

Acrivon Therapeutics Earnings release: Q1 2026


Acrivon Therapeutics Quarterly report: Q1 2026

May 13, 2026, 4:00 PM EDT - 2 months ago

Acrivon Therapeutics Quarterly report: Q1 2026


Acrivon Therapeutics Slides: Corporate presentation

May 13, 2026, 4:00 PM EDT - 2 months ago

Acrivon Therapeutics Slides: Corporate presentation


Acrivon Therapeutics Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 3 months ago

Acrivon Therapeutics Proxy statement: Proxy filing


Acrivon Therapeutics Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 3 months ago

Acrivon Therapeutics Proxy statement: Proxy filing


Acrivon Therapeutics reports Q4 EPS (49c), consensus (46c)

2026-03-19T11:25:53.000Z - 4 months ago

Acrivon Therapeutics reports Q4 EPS (49c), consensus (46c)


Acrivon Therapeutics sees cash runway into 2Q27

2026-03-19T11:25:40.000Z - 4 months ago

Acrivon Therapeutics sees cash runway into 2Q27


Acrivon Therapeutics Earnings release: Q4 2025

Mar 19, 2026, 7:00 AM EDT - 4 months ago

Acrivon Therapeutics Earnings release: Q4 2025


Acrivon Therapeutics Annual report: Q4 2025

Mar 19, 2026, 7:00 AM EDT - 4 months ago

Acrivon Therapeutics Annual report: Q4 2025


Acrivon Therapeutics Slides: FY 2026

Feb 27, 2026, 8:00 AM EST - 5 months ago

Acrivon Therapeutics Slides: FY 2026


Acrivon Therapeutics Transcript: Study Update

Jan 8, 2026, 8:30 AM EST - 7 months ago

Acrivon Therapeutics Transcript: Study Update


Acrivon Therapeutics Press release: Study Update

Jan 8, 2026, 8:30 AM EST - 7 months ago

Acrivon Therapeutics Press release: Study Update


Acrivon Therapeutics Slides: Study Update

Jan 8, 2026, 8:30 AM EST - 7 months ago

Acrivon Therapeutics Slides: Study Update


Acrivon Therapeutics announces progress across pipeline

2026-01-08T12:35:54.000Z - 7 months ago

Acrivon Therapeutics announces progress across pipeline


Acrivon to provide ACR-368, ACR-2316 clinical data in January

2025-12-17T12:36:13.000Z - 7 months ago

Acrivon to provide ACR-368, ACR-2316 clinical data in January


Acrivon Therapeutics reports Q3 EPS (47c), consensus (58c)

2025-11-13T21:50:27.000Z - 9 months ago

Acrivon Therapeutics reports Q3 EPS (47c), consensus (58c)


Acrivon Therapeutics Earnings release: Q3 2025

Nov 13, 2025, 7:00 AM EST - 9 months ago

Acrivon Therapeutics Earnings release: Q3 2025


Acrivon Therapeutics Quarterly report: Q3 2025

Nov 13, 2025, 7:00 AM EST - 9 months ago

Acrivon Therapeutics Quarterly report: Q3 2025


Acrivon Therapeutics reports Q2 EPS (55c), consensus (58c)

2025-08-13T20:45:13.000Z - 1 year ago

Acrivon Therapeutics reports Q2 EPS (55c), consensus (58c)


Acrivon Therapeutics Quarterly report: Q2 2025

Aug 13, 2025, 4:00 PM EDT - 1 year ago

Acrivon Therapeutics Quarterly report: Q2 2025


Acrivon Therapeutics Earnings release: Q2 2025

Aug 13, 2025, 4:00 PM EDT - 1 year ago

Acrivon Therapeutics Earnings release: Q2 2025


Acrivon Therapeutics Slides: Corporate Presentation

Jun 13, 2025, 10:00 AM EDT - 1 year ago

Acrivon Therapeutics Slides: Corporate Presentation


Acrivon Therapeutics Quarterly report: Q1 2025

May 14, 2025, 12:00 AM EDT - 1 year ago

Acrivon Therapeutics Quarterly report: Q1 2025


Acrivon Therapeutics Earnings release: Q1 2025

May 14, 2025, 12:00 AM EDT - 1 year ago

Acrivon Therapeutics Earnings release: Q1 2025


Acrivon Therapeutics Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Acrivon Therapeutics Proxy statement: Proxy Filing


Acrivon Therapeutics Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Acrivon Therapeutics Proxy statement: Proxy Filing


Acrivon Therapeutics Earnings release: Q4 2024

Mar 26, 2025, 7:00 PM EDT - 1 year ago

Acrivon Therapeutics Earnings release: Q4 2024


Acrivon Therapeutics Annual report: Q4 2024

Mar 26, 2025, 7:00 PM EDT - 1 year ago

Acrivon Therapeutics Annual report: Q4 2024


Acrivon Therapeutics Transcript: Status Update

Mar 25, 2025, 4:00 PM EDT - 1 year ago

Acrivon Therapeutics Transcript: Status Update


Acrivon Therapeutics Slides: Status Update

Mar 25, 2025, 4:00 PM EDT - 1 year ago

Acrivon Therapeutics Slides: Status Update


Acrivon Therapeutics Quarterly report: Q3 2024

Nov 13, 2024, 7:00 AM EST - 1 year ago

Acrivon Therapeutics Quarterly report: Q3 2024


Acrivon Therapeutics Earnings release: Q3 2024

Nov 13, 2024, 7:00 AM EST - 1 year ago

Acrivon Therapeutics Earnings release: Q3 2024


Acrivon Therapeutics Transcript: Study Update

Sep 14, 2024, 9:00 AM EDT - 2 years ago

Acrivon Therapeutics Transcript: Study Update


Acrivon Therapeutics Press release: Study Update

Sep 14, 2024, 9:00 AM EDT - 2 years ago

Acrivon Therapeutics Press release: Study Update


Acrivon Therapeutics Slides: Study Update

Sep 14, 2024, 9:00 AM EDT - 2 years ago

Acrivon Therapeutics Slides: Study Update


Acrivon Therapeutics Quarterly report: Q2 2024

Aug 13, 2024, 4:00 PM EDT - 2 years ago

Acrivon Therapeutics Quarterly report: Q2 2024


Acrivon Therapeutics Earnings release: Q2 2024

Aug 13, 2024, 4:00 PM EDT - 2 years ago

Acrivon Therapeutics Earnings release: Q2 2024


Acrivon Therapeutics Slides: Corporate Presentation

Jun 4, 2024, 7:00 AM EDT - 2 years ago

Acrivon Therapeutics Slides: Corporate Presentation


Acrivon Therapeutics Quarterly report: Q1 2024

May 14, 2024, 7:00 AM EDT - 2 years ago

Acrivon Therapeutics Quarterly report: Q1 2024


Acrivon Therapeutics Earnings release: Q1 2024

May 14, 2024, 7:00 AM EDT - 2 years ago

Acrivon Therapeutics Earnings release: Q1 2024


Acrivon Therapeutics Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Acrivon Therapeutics Proxy statement: Proxy Filing


Acrivon Therapeutics Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Acrivon Therapeutics Proxy statement: Proxy Filing


Acrivon Therapeutics Transcript: R&D Update

Apr 24, 2024, 4:15 PM EDT - 2 years ago

Acrivon Therapeutics Transcript: R&D Update


Acrivon Therapeutics Slides: R&D Update

Apr 24, 2024, 4:15 PM EDT - 2 years ago

Acrivon Therapeutics Slides: R&D Update


Acrivon Therapeutics Annual report: Q4 2023

Mar 28, 2024, 8:00 AM EDT - 2 years ago

Acrivon Therapeutics Annual report: Q4 2023


Acrivon Therapeutics Earnings release: Q4 2023

Mar 28, 2024, 8:00 AM EDT - 2 years ago

Acrivon Therapeutics Earnings release: Q4 2023


Acrivon Therapeutics Quarterly report: Q3 2023

Nov 9, 2023, 7:00 AM EST - 2 years ago

Acrivon Therapeutics Quarterly report: Q3 2023


Acrivon Therapeutics Earnings release: Q3 2023

Nov 9, 2023, 7:00 AM EST - 2 years ago

Acrivon Therapeutics Earnings release: Q3 2023


Acrivon Therapeutics Quarterly report: Q2 2023

Aug 11, 2023, 7:00 AM EDT - 3 years ago

Acrivon Therapeutics Quarterly report: Q2 2023


Acrivon Therapeutics Earnings release: Q2 2023

Aug 11, 2023, 7:00 AM EDT - 3 years ago

Acrivon Therapeutics Earnings release: Q2 2023


Acrivon Therapeutics Proxy statement: Proxy Filing

May 30, 2023, 8:00 AM EDT - 3 years ago

Acrivon Therapeutics Proxy statement: Proxy Filing


Acrivon Therapeutics Quarterly report: Q1 2023

May 9, 2023, 7:00 AM EDT - 3 years ago

Acrivon Therapeutics Quarterly report: Q1 2023


Acrivon Therapeutics Earnings release: Q1 2023

May 9, 2023, 7:00 AM EDT - 3 years ago

Acrivon Therapeutics Earnings release: Q1 2023


Acrivon Therapeutics Proxy statement: Proxy Filing

May 1, 2023, 8:00 AM EDT - 3 years ago

Acrivon Therapeutics Proxy statement: Proxy Filing


Acrivon Therapeutics Proxy statement: Proxy Filing

May 1, 2023, 8:00 AM EDT - 3 years ago

Acrivon Therapeutics Proxy statement: Proxy Filing


Acrivon Therapeutics Annual report: Q4 2022

Mar 28, 2023, 7:00 AM EDT - 3 years ago

Acrivon Therapeutics Annual report: Q4 2022


Acrivon Therapeutics Earnings release: Q4 2022

Mar 28, 2023, 7:00 AM EDT - 3 years ago

Acrivon Therapeutics Earnings release: Q4 2022


Dani_G_German
Dani_G_German Jul. 24 at 2:34 PM
$ACRV back to consolidation unfortunately Hang in there
1 · Reply
nmarrone2207
nmarrone2207 Jul. 23 at 12:18 PM
$ACRV zoom out and can see a LONG tightening consolidation.... if that plays out we are staying in the 1.50-2 range for months.
2 · Reply
Bullbarbise
Bullbarbise Jul. 23 at 12:14 PM
0 · Reply
dgbio
dgbio Jul. 22 at 6:27 PM
$ACRV "ACR-2316 is currently in a Phase 1/2 clinical study advancing toward the dose expansion phase. Initial observations have shown tumor shrinkage, including PRs, and durable clinical benefit in subjects with small cell lung cancer (SCLC), squamous non-small cell lung cancer (sqNSCLC), and adenosarcoma NSCLC (adNSCLC), AP3-predicted tumor types not previously shown to be sensitive to other clinical WEE1 or PKMYT1 inhibitors". https://ir.acrivon.com/news-releases/news-release-details/acrivon-highlight-power-its-ap3-platform-streamlined-pathway
0 · Reply
Dani_G_German
Dani_G_German Jul. 22 at 3:34 PM
$ACRV stick with it
0 · Reply
ajmrtxl
ajmrtxl Jul. 22 at 3:05 PM
$ACRV 's latest squeeze play
0 · Reply
nmarrone2207
nmarrone2207 Jul. 20 at 9:01 PM
$ACRV 4 hour looks ready to turn up....
0 · Reply
open_outcry
open_outcry Jul. 17 at 2:45 PM
$ACRV seems like nearly everyone on this board is trading this stock from a technical standpoint... i'm invested in this one on substance. it's a LOOOONG hold that will be a 10-bagger (or better). seems like the most obvious and lucrative play with this ticker, given it doesn't swing like some other bios ($CCCC)
2 · Reply
elmono
elmono Jul. 16 at 4:50 PM
$ACRV basically a turd 😂😂😂
1 · Reply
Bullbarbise
Bullbarbise Jul. 16 at 2:51 PM
$ACRV weeks to recover a fraction of what lost in the past. And in a single day and after a small recover 2 consecutive vomit days where in few minutes goes to loose all what recoverred. Wasted time, wasted money. Unbeliavable. I'll start to sell my shares and never again. Better spend money in other intelligent ways
1 · Reply
aquira
aquira Jul. 16 at 1:52 PM
$ACRV fooken disaster. This stock just pingpong between 1.5 to 2. What a fooken waste of time and money. Same with $BMEA
1 · Reply
TheLearnerEarner
TheLearnerEarner Jul. 15 at 4:09 PM
$ACRV ✅ Healthcare - Small Cap - Momentum Trap Price To Book: 0.79 (bargain value) F-Score: 2/9 🏦 1 Month Performance: 31% Analysts: 7x buy ratings 👨‍🔬 Highest Analysts Price Target: $19.00 (792% above Price) 🌟 (last 3 months) Range (12m) $1.20 - $3.56 💰 RSI: 58.54 (bullish) 📊 NEWSDESK (last recent article) 📰 https://uk.finance.yahoo.com/news/acrivon-therapeutics-present-td-cowen-113000590.html
1 · Reply
elmono
elmono Jul. 15 at 3:29 PM
$ACRV is there a logical explanation for a -10% shit the bed sell off…just wondering
2 · Reply
MrTicker
MrTicker Jul. 14 at 6:56 PM
$ACRV low volume uptrend with power hour around the corner. Push through $2.16 for a new HOD with volume and this start the run
0 · Reply
nmarrone2207
nmarrone2207 Jul. 14 at 1:58 PM
$ACRV 2.18 coming
0 · Reply
blackpoint01
blackpoint01 Jul. 9 at 8:05 PM
$ACRV these people don’t know how to read a chart and start throwing numbers outhere.! The resistance is located at where the stock got rejected before a downtrend which it was at 2.19 to 2.24 that’s where the real resistance is at.!
1 · Reply
Bullbarbise
Bullbarbise Jul. 9 at 3:19 PM
$ACRV it will try again 2.09
0 · Reply
Dani_G_German
Dani_G_German Jul. 9 at 3:11 PM
$ACRV look for it to cross 2.09 That will be confirmation for reversal
0 · Reply
Monty3030
Monty3030 Jul. 9 at 10:13 AM
$ACRV We need to break $3.56 for big breakout!!
0 · Reply
Dani_G_German
Dani_G_German Jul. 8 at 6:01 PM
$ACRV 2.09 is the obstacle
1 · Reply
PreGigs
PreGigs Jul. 8 at 1:51 PM
0 · Reply
theBigDollarski
theBigDollarski Jul. 8 at 1:50 PM
0 · Reply